Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Washington
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Swiss Cancer Institute
RenJi Hospital
National Cancer Institute (NCI)
Assiut University
University of Washington
M.D. Anderson Cancer Center
G1 Therapeutics, Inc.
Columbia University
Merck Sharp & Dohme LLC
Nagoya University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Zhujiang Hospital
Radiation Therapy Oncology Group
SWOG Cancer Research Network
Fudan University
Hoosier Cancer Research Network
The University of Texas Health Science Center at San Antonio
Mayo Clinic
Radiation Therapy Oncology Group
Masonic Cancer Center, University of Minnesota
University Health Network, Toronto
UNICANCER
Memorial Sloan Kettering Cancer Center
Fox Chase Cancer Center
The University of Texas Health Science Center, Houston
Cardiff University
Wake Forest University Health Sciences
Radiation Therapy Oncology Group
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Hellenic Oncology Research Group
University of Chicago
University of Chicago
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
SWOG Cancer Research Network
M.D. Anderson Cancer Center
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
AstraZeneca
National Cancer Institute (NCI)